Deimmunization of Monoclonal Antibodies
Authors:
- 10 December 2008
- book chapter
- Published by Springer Nature
- Vol. 525, 405-423
Abstract
Immunogenicity is a major limitation to therapy with certain monoclonal antibodies and proteins. A major driver for immunogenicity is the presence of human T-cell epitopes within the protein sequence which can activate helper T-cells resulting in the sustained production of antibodies and neutralization of the therapeutic effect. Deimmunization is a new technology for location and removal of T-cell epitopes through the combined use of immunological and molecular biology techniques. In the case of deimmunization of antibodies, mutations to remove T-cell epitopes can generally be introduced without significantly reducing the binding affinity of the antibody. Typically, “deimmunized” antibodies are created with human constant regions and by expression of genes encoding these antibodies in mammalian cells. This chapter details a method for creation of a deimmunized antibody for production in mammalian cells.Keywords
This publication has 7 references indexed in Scilit:
- Evolutionary deimmunization: An ancillary mechanism for self-tolerance?Cellular Immunology, 2006
- Overcoming the immunologic response to foreign enzymes in cancer therapyExpert Review of Clinical Immunology, 2005
- Identification and removal of a promiscuous CD4+ T cell epitope from the C1 domain of factor VIIIJournal of Thrombosis and Haemostasis, 2005
- The Development of a Modified Human IFN-α2b Linked to the Fc Portion of Human IgG1 as a Novel Potential Therapeutic for the Treatment of Hepatitis C Virus InfectionJournal of Interferon & Cytokine Research, 2004
- Cloning immunoglobulin variable domains for expression by the polymerase chain reaction.Proceedings of the National Academy of Sciences, 1989
- Reshaping human antibodies for therapyNature, 1988
- Transfectomas Provide Novel Chimeric AntibodiesScience, 1985